Avelo Airlines is opening a base at McKinney National Airport later this year, becoming the first carrier to offer passenger ...

In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.

Patients with acute lymphoblastic leukemia (ALL) who have an ABL-class fusion had better outcomes than a control group when treated with tyrosine kinase inhibitors at their first relapse, according to ...

Neoadjuvant TKI therapy in non-metastatic GIST patients can reduce surgical complexity, with CE-CT imaging predicting benefits in 22 of 39 patients. Significant tumor volume reduction was observed ...

About 1 in every 526 people in the U.S. will be diagnosed with chronic myeloid leukemia (CML) this year, but most of these people will achieve their normal life expectancy thanks to tyrosine kinase ...

CT scan of chest, abdomen, and pelvis shows high-disease burden, including multiple mediastinal and hilar nodes, deposits in ...

Can adding a TKI that targets programmed death ligand 1 (PD-L1) to a monoclonal antibody that also targets PD-L1 improve outcomes over the monoclonal antibody alone in locally advanced, unresectable ...

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for ...

BEDFORD, Mass., June 10, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development and commercialization of innovative ...

BEDFORD, Mass., Feb. 11, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix (OCUL), Inc. , a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies ...